Table 3.
Comparative of maintenance of remission at 12 mo in patients with initial remission in both groups
Infliximab original group | 95%CI | CT-P13 group | 95%CI | P value | Rate Difference (95%CI) | |
Maintained basal remission at 12 mo | 62/74 (83.7%) | 74.7-92.9 | 54/74 (72.9%) | 62.2-83.5 | 0.162 | -0.037-0.253 |
Maintained basal remission at 12 mo CD | 42/51 (82.3%) | 70.9-93.8 | 37/53 (69.8%) | 56.5-83.1 | 0.205 | -0.056-0.307 |
Maintained basal remission at 12 mo UC | 20/23 (87%) | 66.4-97.2 | 17/21 (81.0%) | 62.5-92.5 | 0.890 | -0.203-0.23 |
CD: Crohn's disease; UC: Ulcerative colitis.